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Purpose: To evaluate the performance of the hippocampal normal tissue complication
model that relates dose to the bilateral hippocampus tomemory impairment at 18months
post-treatment in a population of low-grade glioma (LGG) patients.
Methods: LGG patients treated within the radiotherapy-only arm of the EORTC
22033-26033 trial were analyzed. Hippocampal dose parameters were calculated from
the original radiotherapy plans. Difference in Rey Verbal Auditory Learning test delayed
recall (AVLT-DR) performance pre-and 18 (±4) months post-treatment was compared to
reference data from the Maastricht Aging study. The NTCP model published by Gondi
et al. was applied to the dosimetric data and model predictions were compared to actual
neurocognitive outcome.
Results: A total of 29 patients met inclusion criteria. Mean dose in EQD2Gy to the
bilateral hippocampus was 39.8Gy (95% CI 34.3–44.4Gy), the median dose to 40% of
the bilateral hippocampus was 47.2 EQD2Gy. The model predicted a risk of memory
impairment exceeding 99% in 22 patients. However, only seven patients were found to
have a significant decline in AVLT-dr score.
Conclusions: In this dataset of only LGG patients treated with radiotherapy the
hippocampus NTCP model did not perform as expected to predict cognitive decline
based on dose to 40% of the bilateral hippocampus. Caution should be taken when
extrapolating this model outside of the range of dose-volume parameters in which it
was developed.
Keywords: NTCP (normal tissue complication probability) model, low grade glioma (LGG), model verification and
validation, neurocognition, memory, late effect of cancer treatment, radiotherapy—adverse effects
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INTRODUCTION
Low grade glioma (LGG) are a group of relatively slow
growing primary brain neoplasms, mainly occurring in those
between 30 and 50 years of age (1, 2). Modern treatment
for LGG patients comprises surgery followed by radiotherapy
and adjuvant chemotherapy (3). Overall survival was recently
reported to be 13.3 years (4), but can vary withmolecular subtype.
With many LGG patients living for many years or even
decades after treatment, the late adverse effects of treatment on
quality of life and neurocognitive functioning are of increasing
importance. Although both the tumor itself, as well as the
use of anticonvulsant therapy, have a deleterious effect on
neurocognitive function (5, 6), radiotherapy (RT) in particular
has been associated with a negative impact on neurocognitive
function. This late effect of radiotherapy was found in several
series with a longer follow-up (7, 8), however, it was not found in
several studies that limited observation to the first 5 years (9–12).
A dose response relationship with decreasing neurocognitive
performance (specifically memory) has been attributed to the
hippocampal area (13). A NTCP model for memory impairment
was proposed by Gondi et al. (14). In this study, 18 patients
undergoing fractionated stereotactic radiotherapy for benign
and low-grade tumors (9 vestibular schwannomas, 2 pituitary
adenomas, 3meningiomas, and 4 low grade gliomas) completed a
comprehensive baseline neurocognitive assessment and a repeat
assessment at 18 months. A control group of 6 non-irradiated
subjects was tested as well, allowing for the use of Z scores for
performance change. Dose in excess of 7.3 EQD2Gy to 40% of
bilateral hippocampus were found to be significantly correlated
to a decrease in Wechsler Memory Scale III–Word Lists delayed
recall score, a test that measures verbal memory performance.
Although this model is routinely used in the clinic, its
performance has not yet been quantified in the setting of partial
brain irradiation in a population of LGG patients. We analyzed
data from a recently completed and published randomized
phase III trial, where LGG patients in the control arm were
treated exclusively with focal radiotherapy up to 50.4Gy (15) and
compared the predicted risk of neuropsychological impairment
with the actual outcome.
MATERIALS AND METHODS
Patient Population
Data was acquired within the EORTC 22033-26033
(NCT00182819) trial, which is a prospective, randomized,
open-label, phase 3 Intergroup study (European Organisation
for Research and Treatment of Cancer [EORTC] Radiotherapy
and Brain Tumor Groups, National Cancer Institute of Canada
[NCIC] Clinical Trials Group, Trans Tasman Radiation
Oncology Group [TROG], Medical Research Council [MRC]
Clinical Trials Unit). The study was approved by the institutional
review boards and ethics committees of all participating centers.
All patients provided written informed consent at the time of
registration (15).
In the aforementioned trial, patients of 18 years of age or older
with histologically confirmed and centrally reviewed low-grade
(WHO 2) glioma (diffuse astrocytoma, oligoastrocytoma and
oligodendroglioma, WHO classification 2006) with at least one
high-risk feature (age >40 years, progressive disease, tumor
size >5 cm, tumor crossing midline, any focal neurological
deficit) were randomly assigned to treatment with either
radiotherapy (28 × 1.8Gy) or temozolomide chemotherapy.
Between September 2005 and March 2010 477 patients were
randomized. The study design, treatment details and the results
of the primary analysis have been described elsewhere (15).
A total of 103 patients from preselected medical centers also
underwent a detailed neurocognitive examination consisting
of the Rey Auditory Verbal Learning test (AVLT), Concept
Shifting test, Categoric Word Fluency test, and the Digit-
Symbol Substitution test. Neurocognitive tests were conducted
at randomization and then every 6 months until to tumor
progression or death.
The analysis presented herein contains patients with
retrievable radiotherapy planning data and neuropsychological
testing at both baseline and 18 (±4 months). The neurocognitive
analysis for the entire patient population of EORTC 22033-26033
is reported elsewhere (16). The present study was conducted
according to the principles of the Declaration of Helsinki
(59th WMA General Assembly, Seoul, October 2008) and in
accordance with the local medical research regulations. The
study protocol has been presented to the local Medical Ethics
Committee (MEC-2017-321). No ethical approval was deemed
necessary and the requirement for additional informed consent
was waived.
Neuropsychological Assessments
One of the tests in the neuropsychological assessment is the
AVLT, which calls for various aspects of learning and recall.
The delayed recall condition (AVLT-dr) requires patients to
memorize a list of 15 words for five consecutive tests, and to recall
these 15 words after 20min. The maximal score is 15 out of 15.
This test is conceptually identical to the delayed recall condition
in the Wechsler Memory Scale 3—word lists used by Gondi et al.
as the primary outcome measure.
In contrast to the original paper by Gondi et al.,
EORTC22033-26033 does not include a control group of
healthy volunteers. Normal data for AVLT-dr, with test-
retest changes, has been published by the Maastricht Aging
Study group (17). This study tested healthy volunteers using
several neuropsychological tests at 2.5 year intervals and gives
parameters for a regression-based change analysis of test-retest
performance. The following relationship between age and change
in AVLT-dr retest score was found.
E = 1.025− 0.035 ∗ (age− 62.5) (1)
Where E is the expected change between test and retest-score.
This can be converted to a Z score using the standardized residual
(which was found to be 2.362 in this test condition).
Z = O− E
2.362
(2)
WhereO is the observed retest score, and E is the predicted retest
score. As reported in the paper by Gondi et al., a neurocognitive
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event was defined as a reduction in AVLT-dr score at 18 months
corresponding to a Z score lower than−1.5.
Radiotherapy Treatment
Patients were treated with photon radiotherapy using 3D
conformal radiotherapy (3DCT), fractionated stereotactic
radiotherapy (FSRT) or intensity modulated radiotherapy
(IMRT) techniques depending on the availability at the
institution. Gross tumor volume (GTV) was defined by the
region of high signal intensity on T2 weighted MRI of FLAIR
sequences, or, in case of prior surgery, the resection cavity
and the residual tumor. Clinical target volume (CTV) margin
was 10–15mm. Planning target volume (PTV) margin was
7mm for all patients. As required per protocol the contralateral
hemisphere was spared, but no specific attempt at sparing one or
both hippocampi was made.
Delineation and DVH Analysis
A rigid registration was applied between the planning CT and
MRI using MIMSoftware (Cleveland, OH, USA). Hippocampus
delineation followed the instructions of the publicly available
atlas from RTOG0933 (18). In case no registration was
possible, delineation was performed on CT using anatomical
landmarks visible on MRI. Dose volume histograms (DVH)
and subsequent DVH parameters were generated for left and
right hippocampus individually and for composite bilateral
hippocampi. As presented in the paper by Gondi et al., we
assumed an α/β value of 2 to convert physical dose to biologically
equivalent dose in 2Gy fractions (EQD2 Gy). The Dx% of
bilateral hippocampus was defined as the dose in EQD2 Gy
received by x % of bilateral hippocampal volume.
Statistical Approach
Descriptive statistics were generated for age, tumor laterality,
tumor lobe, anti-epileptic drug treatment (AED), education,
CTV volume, and hippocampal dosimetry (Table 1). The model
used by Gondi et al. is based on the Lyman model (19). Their
formulation was presented as follows:
PNTCP =
1√
2pi
∫ t
−∞
e
−u2
2 du (3)
Where t is a function of TD50, the dose to 40% of hippocampus
at which the probability of neurocognitive decline is 50%, andm,
is a slope parameter (see below).
t = D− TD50
m TD50
(4)
In the paper published by Gondi et al., the obtained values
of TD50 and m were 14.88 and 0.54, respectively. We applied
this model to generate predicted NTCP values for the dose
distributions in our study population. Cases were grouped in
three bins of equal size, according to ascendingNTCP. In order to
compute the observed risk the incidence of a neuropsychological
event in each bin is computed. The predicted NTCP was plotted
against observed NTCP in a calibration plot. Next, a linear
TABLE 1 | Patient characteristics.
Age (years) 43.0 (95% CI 27.8–69.4)
Sex Male 18 62.1%
Female 11 37.9%
Handedness Right 24 82.8%
Left 5 17.2%
Years of education 13.8 (95% CI 12.0–14.4)
Hemisphere Right 10 34.5%
Left 16 55.2%
Both 3 10.3%
Lobe Frontal 10 34.5%
Temporal 6 20.7%
Parietal 2 6.9%
Multifocal 10 34.5%
Other 1 3.4%
CTV volume (cc) 337 (95% CI 278–403)
Number of AEDs 0 3 10.3%
1 2 6.9%
2 24 82.8%
Epilepsy No seizures 9 31.0%
Generalized tonic-clonic
seizures
4 13.8%
Partial seizures 12 41.4%
Other 4 13.8%
Technique 3DCT 23 79.3%
IMRT 3 10.3%
FSRT 3 10.3%
Resection status Biopsy 15 51.7%
Partial removal 12 41.4%
Total removal 2 6.9%
IDH mutation Present 27 98.1%
Absent 1 3.4%
Undetermined 1 3.4%
1p/19q codeletion Present 10 34.4%
Absent 14 48.3%
Undetermined 5 17.2%
For age, CTV volume, and years of education the mean is reported along with the 95%
confidence interval.
regression was performed. The regression coefficients can be used
to calibrate the model to the dataset, the constant can be used as
offset parameter and the slope indicates over- or underestimation
of the observed risk.
In order to quantify model performance, the Brier score (BS)
was calculated for the original formulation of the model. BS is a
measure of the accuracy of a prediction with a binary outcome:
BS = 1
n
∑n
a=1 (fa − oa)
2 (5)
Where n is the number of observations, fa is the probability
that was forecast, and oa is the outcome (1 if the event occurs
and 0 if it does not occur). A low Brier score is indicative of
good model performance, it reflects a strong correlation between
forecast and outcome.
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Other Predictive Parameters
In addition to evaluating the performance of the NTCP model,
we investigated if CTV volume, laterality, age, handedness,
and WHO performance score were associated with cognitive
deterioration. To this end, using Spearman’s correlation
coefficient, a correlation matrix was made to identify if bilateral
and contralateral hippocampal DVH parameters correlated with
cognitive deterioration.
Power Considerations
In the paper by Gondi et al., a lower rate of neurocognitive
impairment was found in the group of patients with a low dose
to bilateral hippocampi, defined as dose to 40% of bilateral
hippocampus volume in EQD2 Gy (D40%BH) ≤7.3Gy (11.1 vs.
66.7%). In order to detect this difference in our group with 80%
power and 2-sided significance level α = 0.05, using a Fischer
exact test, and assuming the low-dose and the high-dose group
are equally sized, 15 patients are required per group. The power
calculation was done in SAS software version 14.1, all other
statistics were done in IBM SPSS Version 24 except for the Brier
score, which was calculated in MATLAB v2017a.
RESULTS
Patient Data
Of 477 patients within EORTC 22033-26033, 103 patients
underwent full neurocognitive testing. Of these, 54 patients
were treated with radiotherapy-only. Of these, 33 patients had a
complete neurocognitive assessment at baseline and at a median
follow up of 18.5 months (95% CI 17.3–18.9). Complete original
dosimetry data was available for 31 patients. Two patients
were excluded due to clinically progressive disease at time of
neurocognitive outcome assessment (Figure 1).
Data of 29 patients from 1 Spanish and 4 Dutch institutes is
summarized in Table 1. Median age of patients at randomization
was 43 years (95% CI 39–47). Only three patients did not require
anti-epileptic medication. Sixteen tumors were left sided, 10
right sided, and three were bilateral. Final resection status was
biopsy only in 15 patients, gross total resection in two patients,
and partial resection in twelve patients. An IDH mutation was
present in 27 patients, absent in one patient and undetermined
in one patient. An 1p/19q codeletion was present in 10 patients,
absent in 14 patients, and undetermined in five patients. Twenty-
eight patients were treated to a dose of 50.4Gy in 28 fractions,
one patient was treated to a dose of 54Gy in 30 fractions.
Twenty-five patients were treated with 3DCT, three with IMRT
and two with fractionated stereotactic radiotherapy. Mean CTV
volume was 340 cc (95% CI 276–403). Mean dose in EQD2
Gy to bilateral hippocampi was 31.4Gy (95% CI 27.2–35.6).
The mean D40%BH was 40.9Gy (95% CI 35.8–46.0), and the
median D40%BH was 47.2Gy. Only one patient had a D40%BH
lower than 7.3Gy. Mean dose in EQD2 Gy to contralateral
hippocampus was 21.6Gy (95% CI 16.7–26.9). Overall, there
was no significant difference between pre- and post-radiotherapy
AVLT-dr score (95% CI 1.09–2.16; Figure 2). A cognitive event
was scored in seven patients (24.1%). At the time of analysis, the
median time to progression in 14 patients was 2.9 years (95% CI
2.2–3.6). Fifteen patients were free of progressive disease after
a median follow-up duration of 3.3 years. We compared the
subgroup of patients with available data (n = 31) with the rest
of the study population (n = 446). The groups were comparable
with respect to tumor laterality, tumor lobe, performance status,
progression free survival, and presence of an 1p/19q codeletion.
However, the number of IDH wildtype tumors was significantly
lower in the study population (3.2 vs. 14%, p = 0.025, see
Supplementary Data).
Model Performance
We were unable to compare the incidence of cognitive events
between the high and low dose group as described in the paper
by Gondi et al. (D40%BH < 7.3Gy) as there was only one case
in the low dose group. However, there was no difference in the
incidence of a cognitive event between the group that received
a D40%BH above vs. below the median (47.2 Gy) in this study
(14 vs. 25%, p = 0.68). NTCP values are presented in Table 2
with dosimetry and neurocognitive results. A calibration plot is
presented in Figure 3. Linear regression showed a constant of
0.03 (p = 0.60) and a slope of 0.24 (p < 0.01) at an r2 of 0.346.
The Brier score of the model was 0.63.
Dosimetric Parameters
A heat map of the correlation matrix is presented in Figure 4.
Increasing age (p = 0.04) and tumor localization in the left
hemisphere (p = 0.01) were related to poorer neurocognitive
outcome at 18 (±4) months. None of the bilateral hippocampal
dose volume parameters (D10%, D20%, D30% up to D90%,
D95% and mean dose) did exhibit a significant correlation
with outcome.
DISCUSSION
To the best of our knowledge, this is the first attempt to
quantify the performance of the hippocampal NTCP model
within a group of only LGG patients treated with partial
brain irradiation. This model was used in RTOG 0933—
hippocampal sparing whole brain radiotherapy vs. standard
whole brain therapy in brain metastases and in the recently
presented phase III trial exploring WBRT plus memantine,
with or without hippocampal avoidance (NRG-CC001) (18,
20). Brain metastases are almost never observed in the
hippocampus, and selective avoidance of this region is not
likely to result in a higher risk of intracranial recurrence (21).
This is less clear in LGG where tumor cells are known to be
present within the entire brain (22). Moreover, subventricular
zone involvement has been shown to be a biomarker for
poor prognosis (23), making the hippocampus a potential
treatment target.
In the calibration procedure, the positive slope in the linear
regression indicates an overestimation of NTCP values by the
model in this dataset. The high Brier score indicates poor model
performance. In comparing the two study groups, the incidence
of a neurocognitive event is similar (29.2 vs. 24.1% in this study)
but the range of hippocampal dose is quite different. The median
D40%BH in the paper by Gondi et al. was 7.3Gy, at above
which a NTCP of 66.7% was observed. By contrast, the median
D40%BH in this paper is 47.2Gy and all but one of the patients
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FIGURE 1 | Inclusion of patients.
in the present study received a D40%BH in excess of 7.3Gy. In
comparing the two groups, there are substantial differences in
the delivery technique and target volume. In the paper by Gondi
et al., most patients were treated without a CTV expansion and
with limited PTV margins (2mm) using highly conformal dose
distributions. In the present study, patients were treated with a
CTV margin of 10–15mm and a larger PTV (7mm) resulting
in substantially larger target volumes, and the delivery technique
was mainly 3DCRT. It is likely that this resulted in higher doses
to bilateral hippocampus in this study, to a degree that almost
none of the patients were in the low dose group. As such, we were
unable to compare the incidence of neurocognitive impairment
between the high dose and the low dose group. However, the
hippocampal doses in this study group are probably a good
representation of the hippocampal dose range found in LGG
patients undergoing radiotherapy. Therefore, this study should
not be read as a formal disapproval of the hippocampal NTCP
model, but rather as a caution toward extrapolating a NTCP
model beyond the dose range in which it was developed. A
similar issue was encountered byMoiseenko in comparing NTCP
models for radiation toxicity to the visual apparatus (24). Since
no significant correlation between dosimetric parameters and
outcome was observed, we were unable to generate an alternative
model from this dataset.
The choice of endpoint, neurocognitive failure at 18 months
after radiotherapy, is debatable in LGG patients. Trials that found
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FIGURE 2 | Histogram of differences in AVLT-dr score per patient (baseline
minus follow-up). Overall, there was no significant difference between pre- and
post-radiotherapy AVLT-dr score.
FIGURE 3 | Calibration plot of the original model in this dataset. The predicted
NTCP is calculated using the NTCP model. The observed NTCP is calculated
by sorting the cases in three bins of ascending risk (horizontal axis), and
computing the incidence of a neuropsychological event in each bin (vertical
axis). The intercept line represents agreement between predicted and
observed NTCP. Error bars are 95% confidence intervals.
TABLE 2 | Dosimetric parameters, expected values derived from the NTCP
model, and cognitive event (see text for definition).
Age Dose to 40% of bilateral
hippocampus (EQD2 Gy)
Predicted NTCP
(NTCP model)
Cognitive
event
48.7 3.21 0.07 No
48.0 7.30 0.17 No
36.3 10.04 0.27 No
69.4 18.45 0.67 Yes
49.2 19.31 0.71 No
45.5 27.24 0.94 No
42.3 28.89 0.96 No
40.3 40.62 >0.99 No
32.9 44.30 >0.99 No
50.8 45.51 >0.99 No
37.1 46.27 >0.99 Yes
35.6 46.52 >0.99 No
40.6 46.79 >0.99 No
41.6 47.08 >0.99 No
50.1 47.18 >0.99 Yes
34.7 47.31 >0.99 No
48.5 47.42 >0.99 No
60.2 47.50 >0.99 Yes
35.9 47.61 >0.99 No
36.3 47.87 >0.99 No
42.5 47.91 >0.99 No
29.5 47.91 >0.99 No
35.2 48.00 >0.99 No
66.5 48.13 >0.99 No
44.3 48.20 >0.99 Yes
34.0 48.43 >0.99 No
50.6 48.73 >0.99 Yes
32.0 48.95 >0.99 No
27.8 50.74 >0.99 No
a significant effect of radiotherapy on neurocognitive function
typically only did so after a follow-up >5 years (7, 8), whereas
several trials with a shorter follow-up found no significant,
or only transient, deleterious effects (9–12, 25). This begs the
question whether neurocognitive impairment at 18 months is
indeed indicative of a persistent neurocognitive deficit.
Although preclinical and radiological (26, 27) data
demonstrated appreciable changes within the hippocampus
after radiotherapy, a relationship between cognitive performance
and a D40% as low as 7.3 EQD2 Gy was not found in the
current study but also not in other studies. In the setting
of prophylactic WBRT in small cell lung cancer and partial
brain irradiation for glioblastoma multiforme, Ma et al. (28)
demonstrated D50% of 22.1Gy to be associated with a 20%
risk of a significant decline in Hopkins Verbal Learning Test
(HVLT)—delayed recall score. Peiffer et al. (29) identified
the volume of bilateral hippocampi receiving 60Gy as a
possible predictor for cognitive decline. The analysis by
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FIGURE 4 | Correlation matrix of clinical and dosimetric parameters. Outcome: neurocognitive event, binary (for definition, see “Methods”), WHO, World Health
Organization Performance score; D10%, 20%, etc., dose absorbed by 10, 20%, etc. of bilateral hippocampus volume. Color: Spearman correlation coefficient. There
are significant correlations between age and outcome, laterality and outcome, and between individual dosimetric parameters.
Okoukoni et al. (30) established a correlation between post-
treatment HVLT score (no baseline measurement was done)
and even higher doses to the bilateral hippocampi. Here,
hippocampal V55Gy of 0, 25, and 50% were associated
with post-radiation impairment rates of 14.9, 45.9, and
80.6%, respectively.
In this study, we used prospectively acquired baseline and
follow up data from the recently completed EORTC22033-26033
trial, ensuring a homogenous patient group with good adherence
to protocol. The subset of patients included in this analysis
is a relatively small proportion of the radiotherapy-only group
(15%). Themain reason for this is that neurocognitive testing was
not mandatory, and a number of centers did no neurocognitive
testing. However, we found no significant differences in clinical
variables (save for presence of IDH mutation) and time to
progressive disease between our subset of and rest of the study
population. In comparing our neurocognitive event-definition to
the one used in the paper by Gondi et al., we did not utilize a
control group but published test-retest data from the Maastricht
Aging study. This data is derived from a study group that is older
(49–56 years), than the average patient in our study (43 years),
and the test-retest interval is twice as long (3 years).
In this dataset of only LGG patients, the NTCP model did
not perform as expected in predicting cognitive decline based
on dose to bilateral hippocampus. Clearly, the understanding
of the relationship between dose to subsites in the CNS and
neurocognitive functioning is still limited, and there exists
a paucity of prospective neuropsychological and dosimetric
parameters with an adequate duration of follow-up.
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